Shook David sold $25K of LYEL
Shook David (Chief Medical Officer) sold 1,977 shares of Lyell Immunopharma, Inc. (LYEL) at $12.64 on 2026-06-10.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider ownership and may marginally affect sentiment, but it does not provide new company fundamentals (no trial, approval, financing, or guidance changes).
Market read
Traders may monitor for follow-on insider activity, but this specific transaction is unlikely to drive a sustained repricing without additional catalysts.
What to watch
Look for whether this sale is part of a broader pattern of officer selling or coincides with upcoming clinical/data milestones; single small sales often revert to noise.
Background
The article is a primary-source SEC Form 4 insider transaction for Lyell Immunopharma.
Ticker impact
Lyell Immunopharma CMO David Shook filed an open-market sale of 1,977 shares at $12.64 on 2026-06-10 (no 10b5-1 plan).
Likely limited near-term impact; any effect would be sentiment-driven and small.
Form 4 insider sales are typically low-signal unless unusually large or paired with other material events; this is a relatively small $25k transaction and lacks a stated 10b5-1 plan.
Market effects
No clear sector read-through; this is company-specific insider activity.
None.
None.
Counterpoint
The absence of a 10b5-1 plan doesn’t necessarily imply negative fundamentals; insiders may sell for diversification/tax needs.
Key entities
- issuerLyell Immunopharma, Inc.
Subject of the Form 4 insider sale by its Chief Medical Officer.
- insiderDavid Shook
Chief Medical Officer who sold 1,977 shares open-market.